Yarrow Bioscience, Inc. Common Stock
YARW
48 hedge funds and large institutions have $64.3M invested in Yarrow Bioscience, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 4 closing their positions.
2% more capital invested
Capital invested by funds: $63M → $64.3M (+$1.28M)
0% more funds holding
Funds holding: 48 → 48 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.92M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$450K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$217K |
| 4 |
Renaissance Technologies
New York
|
+$117K |
| 5 |
Goldman Sachs
New York
|
+$100K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.97M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$800K |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$633K |
| 4 |
DM
Deerfield Management
New York
|
-$446K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$267K |
YARW Hedge Fund Activity: Q4 2019 in Review
48 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q4 2019, worth a combined $64.3M — up 2% from $63M a quarter earlier.
Fund positioning in YARW was balanced in Q4 2019: 4 funds opened new positions, 4 closed out, 13 added to existing stakes and 14 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $3.92M. The largest seller was OrbiMed, exiting entirely with an estimated $2.97M sold.
- 48 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $64.3M of Yarrow Bioscience, Inc. Common Stock stock for Q4 2019, up 2% quarter-over-quarter.
- 4 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q4 2019 and 4 closed out, a net change of 0 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q4 2019 was Ameriprise, an estimated $3.92M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q4 2019 was OrbiMed, an estimated $2.97M sold.
Based on aggregated 13F filings for Q4 2019.